Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex
Life Science Alliance · 2024-05 · 7 (5) · e202302245
DOI: 10.26508/lsa.202302245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 07.03.2024. Verfasst von Andreas Damianou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK andreas.damianou@ndm.ox…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Pfizer, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
KRAS is a proto-oncogene encoding a small GTPase. Mutations contribute to ∼30% of human solid tumours, including lung adenocarcinoma, pancreatic, and colorectal carcinomas. Most KRAS activating mutations interfere with GTP hydrolysis, essential for its role as a molecular switch, leading to alterations in their molecular environment and oncogenic signalling. However, the precise signalling cascades these mutations affect are poorly understood. Here, APEX2 proximity labelling was used to profile the molecular environment of WT, G12D, G13D, and Q61H-activating KRAS mutants under starvation and stimulation conditions. Through quantitative proteomics, we demonstrate the presence of known KRAS interactors, including ARAF and LZTR1, which are differentially captured by WT and KRAS mutants. Notably, the KRAS mutations G12D, G13D, and Q61H abrogate their association with LZTR1, thereby affecting turnover. Elucidating the implications of LZTR1-mediated regulation of KRAS protein levels in cancer may offer insights into therapeutic strategies targeting KRAS-driven malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK andreas.damianou@ndm.ox.ac.uk.
- Chinese Academy for Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Center for Health Data Science, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
- NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Andreas Damianou, Iolanda Vendrell, Benedikt M Kessler
Förderung
- Medical Research Council
- Pfizer
- Chinese Academy of Medical Sciences
- Innovation Fund for Medical Science
- China
- EPSRC
Zitieren
APA
Damianou, A., Liang, Z., Lassen, F., Vendrell, I., Vere, G., Hester, S., Charles, P. D., Pinto-Fernandez, A., Santos, A., Fischer, R., & Kessler, B. M. (2024). Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex. Life Science Alliance, 7(5), e202302245. https://doi.org/10.26508/lsa.202302245
Vancouver
Damianou A, Liang Z, Lassen F, Vendrell I, Vere G, Hester S, et al. Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex. Life Science Alliance. 2024;7(5):e202302245. doi:10.26508/lsa.202302245
BibTeX
@article{Damianou2024,
author = {Damianou, Andreas and Liang, Zhu and Lassen, Frederik and Vendrell, Iolanda and Vere, George and Hester, Svenja and Charles, Philip D and Pinto-Fernandez, Adan and Santos, Alberto and Fischer, Roman and Kessler, Benedikt M},
title = {Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {5},
pages = {e202302245},
doi = {10.26508/lsa.202302245}
}
EUVIMED